Theravance Biopharma's Phase 3 CYPRESS study of ampreloxetine showed no statistically significant primary endpoint results. An FDA meeting indicates further discussions for developing the treatment continue.

Key Highlights

  • The primary endpoint of the CYPRESS study did not reach statistical significance.
  • In post hoc analyses, ampreloxetine demonstrated potential treatment effects in specific patient populations.
  • Theravance Biopharma held a Type B FDA meeting, indicating ongoing regulatory discussions related to ampreloxetine.

Theravance Biopharma, Inc. (NASDAQ: TBPH) released findings from the Phase 3 CYPRESS study of ampreloxetine, revealing that the primary endpoint change in the Orthostatic Hypotension Symptom Assessment (OHSA) composite score at week 8 was not statistically significant. This result suggests challenges in the overall efficacy of ampreloxetine for treating neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA). The study's lack of significant findings could impact the future clinical development and regulatory considerations surrounding the medication.

Study Findings and Implications

The Phase 3 CYPRESS study was intended to assess the efficacy of ampreloxetine in patients with symptomatic nOH associated with MSA. In post hoc analyses, while the primary endpoint did not meet statistical significance, adjustments in secondary efficacy measures indicated possible treatment benefits. The data showed trends that could support a potential pharmacologic effect in certain patient subsets.

These explorations highlight variability in treatment responses, underscoring the complexity of this rare disorder and the potential need for more focused patient criteria in future trials.

Regulatory Interactions with the FDA

The FDA expressed that the current data package was insufficient for approving ampreloxetine but acknowledged the potential of future key trials based on data from earlier studies. A follow-up Type C meeting has been requested by the company to discuss study design aspects that may pave the way for a potential future Marketing application. These interactions signify ongoing regulatory consideration and the critical path forward for ampreloxetine.

Safety and Tolerability Data

Ampreloxetine was generally well tolerated among participants in the study. Of 129 subjects treated, 64.3% experienced treatment-emergent adverse events, with most classified as mild. Serious adverse events were reported in 2 subjects, corresponding to 1.6% of participants, indicating that significant safety concerns did not arise during the trial.

This favorable safety profile, alongside discussions about the clinical data collected, may contribute to regulatory evaluations despite the efficacy hurdles faced.

What's Next for Theravance Biopharma

Moving forward, Theravance Biopharma's next steps will revolve around leveraging insights gained from the ongoing discussions with the FDA and refining the study design for potential subsequent trials. The company aims to further investigate the nuances observed in the patient populations showcasing potential benefit, which could refine treatment protocols. The anticipated results from the follow-up meeting with the FDA will be critical as the firm seeks clarity on regulatory pathways and additional clinical requirements.